Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)
* Patients on hemodialysis (HD) or peritoneal dialysis (PD)
* Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent
You may not be if
1. Acute Kidney Injury (AKI) without underlying chronicity
2. Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
3. Refusal or inability to provide consent
4. Current enrollment in an interventional trial that restricts real-world data collection
5. Life expectancy \< 3 months, where follow-up is not feasible
6. Known contraindications to Daprodustat as per local prescribing information
